Trial Profile
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Vutrisiran (Primary) ; Patisiran
- Indications Transthyretin-related hereditary amyloidosis
- Focus Registrational; Therapeutic Use
- Acronyms HELIOS-A
- Sponsors Alnylam Pharmaceuticals
- 16 Feb 2024 This trial has been completed in Germany, according to the European Clinical Trials Database record.
- 31 Jul 2023 Results assessing quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy over 18 months published in the Neurology and Therapy
- 04 May 2023 According to an Alnylam pharmaceuticals media release, the company intends to present results from this trial at the Italian Association for the Study of the Peripheral Nervous System (ASNP) conference 2023.